Complete guides, comparisons and scientific analyses on peptides in skincare, health and biohacking.
Most human NAD+ trials test oral precursors. The published data on injected NAD+ remain scarce, small, and mostly uncontrolled.
A detailed, source-by-source look at lean mass changes in the semaglutide and tirzepatide trials, what DXA and MRI can and cannot tell us, and why strength data matter more than scan numbers.
A factual review of the STEP 1 extension, STEP 4 and SURMOUNT-4: how much weight returned, how quickly, and what happened to cardiometabolic markers once the medication was withdrawn.
A neutral look at biotinyl-GHK, the peptide sold inside Procapil, separating manufacturer claims, in vitro work, and published human studies.
A straight answer first, then a close look at the small number of randomized trials that measured body fat, fat-free mass and appetite, and at what those trials still cannot tell us.
A neutral, evidence-based safety review of melanotan I, melanotan II, and afamelanotide, the one melanocortin analogue that regulators have actually authorized.
A source-based review of adverse reactions, IGF-1 elevation, glucose monitoring and contraindications in the population where tesamorelin was studied: adults living with HIV who have lipodystrophy.
A neutral review of the safety evidence behind the tripeptide Lys-Pro-Val, where that evidence comes from, and why the gaps matter more than the reassurances.
Vendor codes we tested on a real cart, a daily price tracker that compares each price with its 30-day low, and the Peptide Lab offer.
Epitalon has no FDA approval. Since the HHS enforcement discretion policy of October 28, 2026, a state-licensed pharmacy, a federal facility or a licensed physician may compound epitalon acetate for injection, but only if every listed condition is met.
KPV has no FDA approval. Since October 2026, a narrow and temporary federal enforcement policy describes when a licensed US pharmacy or physician may compound KPV acetate for a named patient.
Semax is not an FDA approved drug. Since October 28, 2026, HHS has said it does not intend to act against certain compounders who prepare it under a narrow set of conditions. Here is the exact scope of that statement.